Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer

Cancer Treatment Reviews

Volumn 26, Issue 1, 2000, Pages 53-65

  Diel, Ingo J ^a   Cote, R J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

BONE MARROW; BONE MARROW BIOPSY; BONE MARROW PURGING; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; EPITHELIUM CELL; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MARKER GENE; METASTASIS; MINIMAL RESIDUAL DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; TUMOR CELL;

EID: 0033956924     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0150     Document Type: Review

References (108)

1. Asworth T. R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 14:1869;146.
2. Engell H. C. Cancer cells in the circulating blood. Acta Chir Scand. 1955;Suppl.
3. Christopherson W. Cancer cells in the peripheral blood: a second look. Acta Cytol. 9:1965;169-174.
4. Ingle J. N., Tormey D. C., Tan H. K. The bone marrow examination in breast cancer. Cancer. 41:1978;670-674.
5. Landys K. E. Prognostic value of bone marrow biopsies in breast cancer. Cancer. 49:1982;513-518.
6. Diel I. J., Krempien B., Kaufmann M., Costa S. D., Goerner R., von Fournier D., Bastert G. Ergebnisse von Beckenkammbiopsien von 475 Patientinnen mit primärem und metastasiertem Mammakarzinom. Tumordiagn u Ther. 13:1992;85-90.
7. Frey U., Senn H. J. Nachweis ossärer Tumormikrometastasen: Vergleich der Aussagekraft von Knochenmarkszytologie und -histologie. Schweiz Med Wschr. 108:1978;82.
8. Sloane J. P., Ormerod M. C., Neville A. M. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res. 40:1980;3079-3082.
9. Sloane J. P., Ormerod M. G., Imrie S. F., Coombes R. C. The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer. 42:1980;392-398.
10. Sloane J. P., Ormerod M. G. Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer. 47:1981;1786-1795.
11. Dearnaley D. P., Sloane J. P., Ormerod M. G., Steele K., Coombes R. C., Clink H. McD., Powles T. J., Ford H. T., Neville A. M. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer. 44:1981;85-90.
12. Dearnaley D. P., Sloane J. P., Imrie S. F., Coombes R. C., Ormerod M. G., Lumley H., Jones M., Neville M. Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J Roy Soc Med. 76:1983;359-364.
13. Redding W. H., Coombes R. C., Monaghan P., Clink H. McD., Imrie S. F., Dearnaley D. P., Ormerod M. G., Sloane J. P., Gazet J. C., Powles T. J., Neville A. M. Detection of micrometastases in patients with primary breast cancer. Lancet II. 1983;1271-1274.
14. Diel I. J., Kaufmann M., Costa S. D., Bastert G. Monoclonal antibodies to detect breast cancer cells. De Vita V. T., Hellman S., Rosenberg S. A. Important advances in oncology. 1994;143-164 Lippincott, Philadelphia.
15. Pantel K., Itzbicki J., Angstwurm M., Hönsinger K., Thetter O., Riethmüller G. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 347:1996;649-653.
16. Chaiwun B., Saad A., Groshen S. Immunohistochemical detection of occult carcinoma in bone marrow and blood: Critical analysis of efficiency of separation, preparation, and limits of detection in a model sytem. Diagn Oncol. 2:1992;267-276.
17. Mansi J. L., Easton D., Berger U., Gazet J. C., Ford H. T., Dearnaley D. P., Coombes R. C. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years Follow-up. Eur J Cancer. 27:1991;1552-1555.
18. Diel I. J., Kaufmann M., Solomayer E. F., Wallwiener D., Gollan Ch, Goerner R., Kaul S., Costa S. D., von Minckwitz G., Holle R., Bastert G. Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus bei 1026 Patientinnen mit primärem Mammakarzinom. Geburtsh u Frauenheilk. 57:1997;333-341.
19. Landys K., Persson S., Kovarik J., Hultborn R., Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat. 49:1998;27-33.
20. Solomayer E. F., Diel I. J., Krempien B., Meyberg G. C., Gollan Ch, Krainick U., Wallwiener D., Bastert G. Results of iliac crest biopsies taken from 1465 patients with primary breast cancer. J Cancer Res Clin Oncol. 124:1998;44-48.
21. Osborne M. P., Rosen P. P. Detection and management of bone marrow micrometastases in breast cancer. Oncology. 8:1994;25-31.
22. Pelkey T. J., Frierson H. F., Bruns D. E. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem. 42:1996;1369-1381.
23. Harbeck N., Abdulsalam A., Jänicke F. Clinical relevance of detection of tumor cells in the bone marrow of primary breast cancer patients: A review. Onkologie. 20:1997;387-392.
24. Jauch K. W., Friess S., Grützner U., Heiss M. M., Funke I. Prognostic significance of micrometastases. Onkologie. 18:1995;525-532.
25. Pantel K., Felber E., Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother. 3:1994;315-322.
26. Pantel K., Riethmüller G. Methods for Detection of micrometastatic carcinoma cells in bone marrow, blood and lymph nodes. Onkologie. 18:1995;394-401.
27. Braun S., Müller M., Hepp F., Schlimok G., Riethmüller G., Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status (correspondence). J Natl Cancer Inst. 90:1998;1099-1100.
28. Braun S., Pantel K. Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat. 52:1998;201-216.
29. Ahr A., Scharl A., Müller M., von Minckwitz G., Gätje R., Pantel K., Kaufmann M. Cross-reactive staining of normal bone marrow cells by monoclonal antibody 2E11. Int J Cancer. 84:1999;502-505.
30. Brugger W., Bühring H. J., Grünebach F., Vogel W., Müller R., Brümmendorf T. H., Ziegler B. L., Rappold I., Brossart P., Scheding S., Kanz L. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol. 17:1999;1535-1544.
31. Schlimok G. Techniken zur Erkennung minimal residueller Erkrankung: Zytologie. Onkologe. 3:1997;293-297.
32. Viglione M., Thor A. Application of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Lab Invest. 56:1987;83.
33. Thor A., Viglione M. J., Ohuchi N., Simpson J., Steis R., Cousar J., Lippman M., Kufe D. W., Schlom J. Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Res Treat. 11:1988;133-145.
34. Mathieu M. C., Friedman S., Bosq J., Caillou B., Spielmann M., Travagli J. P., Contesso G. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat. 15:1990;21-26.
35. Pantel K., Schlimok G., Angstwurm M., Weckermann D., Schmaus W., Gath H., Passlick B., Izbicki J. R., Riethmüller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 3:1994;165-173.
36. Osborne M. P., Wong G. Y., Asina S., Old L. J., Cote R. J., Rosen P. P. Cancer Res. 51:1991;2706-2709.
37. Schlimok G., Funke I., Holzmann B., Göttlinger G., Schmidt G., Häuser H., Swierkot S., Warnecke H. H., Schneider B., Koprowski H., Riethmüller G. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 84:1987;8672-8676.
38. Ellis G., Ferguson M., Yamanaka E., Livingston R. B., Gown A. M. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer. 63:1989;2509-2514.
39. Osborne M. P., Asina S., Wong G. Y., Old L. J., Cote R. J. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. Cancer Res. 49:1989;2510-2513.
40. Pantel K., Cote R. J., Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 91:1999;1113-1124.
41. Coombes R. C., Dearnaley D. P., Buckman R., Jones J. M., Ormerod M. G., Sloane J. P., Powles T. J., Gazet J. C., Ford H. T., Neville A. M. Detection of bone metastases in patients with breast cancer. Invasion Metastasis. 2:1982;177-184.
42. Coombes R. C., Berger U., Mansi J., Redding W. H., Powles T. J., Neville A. M., McKinna A., Nash A. G., Gazet J. C., Ford H. T., Ormerod M., McDonenell T. Prognostic significance of micrometastases in bone marrow of patients with primary breast cancer. NCI Monogr. 1:1986;51-53.
43. Berger U., Bettelheim R., Mansi J. L., Easton D., Coombes R. C., Neville A. M. The relationship between micrometastases in the bone marrow, histopathological features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol. 90:1988;1-6.
44. Mansi J. L., Berger U., Easton D., McDonnell T., Redding W. H., Gazet J. C., McKinna A., Powles T. J., Coombes R. C. Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J. 295:1987;1093-1096.
45. Mansi J. L., Gogas H., Bliss J. M., Gazet J. C., Berger U., Coombes R. C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 354:1999;197-202.
46. Diel I. J., Kaufmann M., Goerner R., Costa S. D., Kaul S., Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol. 10:1992;1534-1539.
47. Diel I. J., Kaufmann M., Costa S. D., Holle R., von Minckwitz G., Solomayer E. F., Kaul S., Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery - prognostic value in comparison to nodal status. J Natl Cancer Inst. 88:1996;1652-1658.
48. Funke I. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol. 16:1998;557-566.
49. Funke I. F. S., Jauch K. W. Tumorzellnachweis im Knochenmark: Entscheidungshilfe zur adjuvanten Therapie bei nodal-negativen Patientinnen mit Mammakarzinom. Chirurg. 62:1991;805-809.
50. Jurcic, J. G. Scheinberg, D. A. Houghton, A. N. Monoclonal antibody therapy of cancer. Cancer Chemotherapy and Biological Response Modifiers Annual 16, Pinedo, H. M.Longo, D. L.Chabner, B. A. 1996, New York, Elsevier, 168, 88.
51. Mansi J. L., Berger U., McDonnell T., Pople A., Rayter Z., Coombes R. C. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol. 7:1989;445-449.
52. Diel I. J., Solomayer E. F., Gollan Ch, Costa S. D., Kaufmann M., Wallwiener D., Bastert G. Prognostic impact of minimal residual disease in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 46/1:1997;Abstr.
53. Riethmüller G., Schneider-Gädicke E., Schlimok G., Schmiegel W. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet. 343:1994;1777-1783.
54. Riethmüller G., Holz E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Funke I., Pichlmair H., Hirche H., Buggisch P., Witte J., Pichlmayr R. Monoclonal antibody therapy for resected Dukes'C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794.
55. Schlimok G., Pantel K., Loibner H., Fackler-Schwalbe I., Riethmüller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer. 31:1995;1799-1803.
56. Diel I. J., Solomayer E. F., Costa S. D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339:1998;357-363.
57. Bezwoda W. R., Seymour L., Dansey R. D. High-dose chemotherapy with hemopoietic rescue as primary treatment for metastatic breast cancer. J Clin Oncol. 13:1995;2483-2489.
58. Kennedy M. J. High dose chemotherapy of breast cancer: Is the question answered? J Clin Oncol. 13:1995;2477-2479.
59. Rahman Z. U., Frye D. K., Buzdar A. U., Smith T. L., Asmar L., Champlin R. E., Hortobagyi G. N. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 15:1997;3171-3177.
60. Cooper B. W., Moss T. J., Ross A. A., Ybanez J., Lazarus H. M. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol. 16:1998;3509-3517.
61. Franklin W. A., Shpall E. J., Archer P., Johnston C. S., Garza-Wiliams S., Hami L., Bitter M. A., Bast R. C., Jones R. B. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 41:1996;1-13.
62. Ross A. A., Cooper B. W., Lazarus H. M., Mackay W., Moss T. J., Ciobanu N., Tallman M. S., Kennedy M. J., Davidson N. E., Sweet D., Winter C., Akard L., Jansen J., Copelan E., Meagher R. C., Herzig R. H., Klumpp T. R., Kahn D. G., Warner N. E. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. J Clin Oncol. 9:1993;2605-2610.
63. Tyer C. L., Vredenburgh J. J., Heimer M., Peters W. P., Bast R. C. Breast cancer cells are effectively purged from peripheral blood progenitor cells with immunomagnetic techniques. Clin Cancer Res. 2:1996;81-86.
64. O'Briant K. C., Shpall E. J., Houston L. L., Peters W. P., Bast R. C. Elimination of clonogenic breast cancer cells from human bone marrow. Cancer. 68:1991;1272-1278.
65. Griwatz C., Brandt B., Assmann G., Zänker K. S. An immunological enrichment method for epithelial cells from peripheral blood. J Immun Methods. 183:1995;251-265.
66. Naume B., Borgen E., Beiske K., Herstad T. K., Ravnas G., Renolen A., Trachsel S., Thrane-Steen K., Funderud S., Kvalheim G. Immunomagnetic Techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematoth. 6:1997;103-114.
67. Ross A. A. Minimal residual disease in solid tumor malignancies: a review. J Hematoth. 7:1998;9-18.
68. Johnson P. W. M., Burchill S. A., Selby P. J. The molecular detection of circulating tumor cells. Br J Cancer. 72:1997;268-276.
69. Zippelius A., Kufer P., Honold G., Köllermann M. W., Oberneder R., Schlimok G., Riethmüller G., Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol. 15:1997;2701-2708.
70. Ghossein R. A., Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer. 78:1996;10-16.
71. Slade M. J., Smith B. M., Sinnett H. D., Cross N. C. P., Coombes R. C. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol. 17:1999;870-879.
72. Traweek S. T., Liu J., Battifora H. Keratin gene expression in non epithelial tissues. Detection with polymerase chain reaction. Am J Pathol. 142:1993;1111-1118.
73. Schoenfeld A., Luqmani Y., Sinnett H. D. Keratin 19 mRNA measurements to detect micrometastases in lymph nodes in breast cancer patients. Cancer Res. 76:1994;1639-1642.
74. Neumaier M., Gerhard M., Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene. 159:1995;43-47.
75. Gunn J., McCall J. L., Yun K., Wright P. A. Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction. Lab Invest. 75:1996;611-616.
76. Noguchi S., Aihara T., Motomura K., Inaji H., Koyama H. Detection of breast cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse-transcriptase polymerase chain reaction. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 23:1996;50-55.
77. Noguchi S., Aihara T., Motomura K., Inaji H., Imaoka S., Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase and polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Path. 148:1996;649-656.
78. Castells A., Boix L., Bessa X., Gargallo L., Pique J. M. Detection of colonic cells in peripheral blood of colorectal cancer patients by means of reverse transcriptase and polymerase chain reaction. Br J Cancer. 78:1998;1368-1372.
79. Mori M., Koshi M., Ueo H. Molecular detection of circulating solid carcinoma cells in the peripheral blood. Int J Cancer. 68:1996;739-743.
80. Wood D. P. Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol. 15:1997;3451-3457.
81. Bostick P. J., Hoon D. S., Cote R. J. Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer [letter]. N Engl J Med. 339:1998;1643-1644.
82. Bostick P. J., Chatterjee S., Chi D., Huynh K., Giuliano A. E., Cote R. J., Hoon D. S. Limitations of specific RT-PCR markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 16:1998;2632-2640.
83. Hoon D. S., Wang Y., Dale P. S., Conrad A. J., Schmid P., Garrison D., Kuo C., Foshag L. J., Nizze A. J., Morton D. L. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 13:1995;2109-2116.
84. Gerhard M., Juhl H., Kalthoff H., Schreiber H. W., Wagener C., Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 12:1994;725-729.
85. Datta Y. H., Adams P. T., Ethier S. P., Terry V. H., Roth M. S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol. 12:1994;475-482.
86. Brown D. C., Purushotham A. D., Birnie G. D., George W. D. Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery. 117:1995;96-101.
87. Moscinski L. C., Trudeau W. L., Fields K. K., Elfenbein G. J. High-sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol. 5:1996;173-180.
88. Fields K. K., Elfenbein G. J., Trudeau W. L., Perkins J. B., Janssen W. E., Moscinski L. C. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol. 14:1996;1868-1876.
89. LeMaire V., Sales J. P., Wind P., Dumas F., Landi B., Fayemendy L., Cugnenc P. H., Gayral F., Lacour B., Loric S. Evaluation and interest in new molecular markers in colon cancer. Annales Pharmaceutiques Francaises. 56:1998;9-17.
90. Cote R. J., Peterson H. F., Chaiwun B., Gelber R. D., Goldhirsch A., Castiglione-Gerstch M., Gusterson B., Neville A. M. The role of immunohistochemical detection of lymph node metastases in the management of breast cancer. Lancet. 354:1999;896-900.
91. Gusterson B. A., Ott R. Occult axillary lymph node micrometastasis in breast cancer. Lancet. 336:1990;434-435.
92. Neville A. M. Breast cancer micrometastases in lymph nodes and bone marrow are prognostically important. Ann Oncol. 2:1991;13-14.
93. Fisher E. R., Swamidoss S., Lee C. H., Rockette H., Redmond C., Fisher B. Detection and significant of occult axillary node metastases in patients with invasive breast cancer. Cancer. 42:1978;2025-2031.
94. Giuliano A. E., Kirgan D. M., Guenther J. M., Morton D. L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 220:1994;391-398.
95. Giuliano A. E., Dale P. S., Turner R. R., Morton D. L., Evans S. W., Krasne D. L. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 222:1995;394-399.
96. Galasko, C. S. B. Skeletal Metastases, Butterworths, London, 1986.
97. Diel, I. J. Kaufmann, M. Bastert, G. Metastatic Bone Disease, Springer, Berlin, Heidelberg, New York, 1994.
98. Pantel K., Schlimok G., Braun S., Kutter D., Lindemann F., Schaller G., Funke I., Izbicki J. R., Riethmüller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 85:1993;1419-1424.
99. Putz E., Witter K., Offner S., Stosiek P., Zippelius A., Johnson J., Zahn R., Riethmüller G., Pantel K. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 59:1999;241-248.
100. Solomayer E. F., Diel I. J., Wallwiener D., Bode S., Meyberg G., Sillem M., Gollan Ch, Kramer M. D., Krainick U., Bastert G. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Oncol. 76:1997;812-818.
101. Solomayer E. F., Diel I. J., Meyberg G. C., Gollan Ch, Bode S., Wallwiener D., Bastert G. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Breast Cancer Res Treat. 49:1998;145-154.
102. Porro G., Ménard S., Tagliabue E., Orefice S., Salvadori B., Squicciarini P., Andreola S., Rilke F., Colnaghi M. I. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer. Cancer. 61:1988;2407-2411.
103. Untch M., Harbeck N., Eiermann W. Micrometastases in bone marrow in patients with breast cancer. Br Med J. 296:1988;290.
104. Salvadori B., Squicciarini B., Rovini D., Orefice S., Andreola S., Rilke F., Barletta L., Ménard S., Colnaghi M. I. Use of monoclonal antibody Mbr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer. 26:1990;865-867.
105. Cote R. J., Rosen P. P., Lesser M. L., Old L. J., Osborne M. P. J Clin Oncol. 9:1991;1749-1756.
106. Harbeck N., Untch M., Pache L., Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer. 69:1994;566-571.
107. Merkle E., Bähr J., Henke A., Bühner M., Martus P. Immunzytochemischer Nachweis von Tumorzellen im Knochenmark als Prognosefaktor beim Mammakarzinom. Geburtsh u Frauenheilk. 54:1994;662-669.
108. Molino A., Pelosi G., Turazza M., Sperotto L., Bonetti A., Nortilli R., Fattovich G., Alaimo C., Piubello Q., Pavanel F., Micciolo R., Cetto G. L. Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat. 42:1997;23-30.